Exponea Provides a Crisis-Communications Tool Free to Organizations Through End of April

Website Slide-ins and Banners enable streamlined communication between brands and their customers, especially during times of crisis

Website Slide-ins and Banners enable streamlined communication between brands and their customers, especially during times of crisis

Today Exponea announced they will be making their Weblayers Starter product available at no cost through the end of April this year to companies needing expedited communication with customers via their website.

Weblayers, sometimes called banners, are notifications that are shown on designated pages to a specified audience. The messages are executed using HTML/CSS/Javascript, unlike typical pop-up banners that are often stopped by ad blockers.

“COVID-19 has dramatically changed the immediacy with which organizations around the world need to communicate,” said Amanda Elam, Chief Marketing Officer. “Consumers are visiting websites looking for quick access to resources and basic information. By making Exponea’s Weblayers Starter product available, customers can remain engaged with the brand and their messaging. Exponea is a global leader in digitally-enabled communications and we are focusing our resources toward helping our customers, partners and community throughout the COVID-19 crisis.”

Exponea will be providing free access through the end of April to its Weblayers Starter product for all customers and brands looking for expedited and easy communication with their customers on the web. The company will also provide a Use Case packet upon request. The packet includes templates for various banners and recommendations on how to utilize multiple channels in coordination with weblayers. Exponea will also host a webinar on Wednesday, March 25th at 11am EDT / 3pm UTC to share examples of how to use the tool. Webinar participants are encouraged to share their examples and challenges. To register for this webinar, click here.

Total
0
Shares
Leave a Reply
Related Posts

Emil Kakkis Joins Nonprofit Biotech Odylia Therapeutics Board of Directors

Emil Kakkis, MD, PhD, joins the Board of Directors of Odylia Therapeutics. Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments for rare and ultra-rare diseases. He brings to Odylia knowledge of the needs and opportunities in developing life-altering therapies for rare diseases. Dr. Kakkis states "Odylia is a unique organization with the potential to truly shift the way therapies are brought to market, ultimately bringing life changing treatments to people living with rare diseases. I'm looking forward to being part of their work."